Showing results (491-500 of 588) with videos related to
Sort By:
Pageof 59
American Heart Journal|September 10, 2018
Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stentsChristine J Chung, Ajay J Kirtane, Yiran Zhang, et al.Genes and Immunity|August 16, 2013
A new regulatory variant in the interleukin-6 receptor gene associates with asthma riskJ A Revez, L Bain, B Chapman, et al.Bioorganic & Medicinal Chemistry Letters|May 9, 2013
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic painScott B Hoyt, Clare London, Catherine Abbadie, et al.Circulation|November 28, 2013
Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) studyBernhard Witzenbichler, Akiko Maehara, Giora Weisz, et al.ACS Medicinal Chemistry Letters|May 26, 2015
Improved Stability of Proline-Derived Direct Thrombin Inhibitors through Hydroxyl to Heterocycle ReplacementHarry R Chobanian, Barbara Pio, Yan Guo, et al.Lancet (London, England)|July 30, 2013
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry studyGregg W Stone, Bernhard Witzenbichler, Giora Weisz, et al.Bioorganic & Medicinal Chemistry Letters|April 26, 2020
Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivationWensheng Yu, Jian Liu, Younong Yu, et al.ACS Medicinal Chemistry Letters|July 18, 2020
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for ClearanceJian Liu, Joseph Kelly, Wensheng Yu, et al.Diabetes|November 25, 2004
A novel glucagon receptor antagonist inhibits glucagon-mediated biological effectsSajjad A Qureshi, Mari Rios Candelore, Dan Xie, et al.Journal of Medicinal Chemistry|April 2, 2021
Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG ActivityWensheng Yu, Jian Liu, Dane Clausen, et al.Pageof 59